Myo-inositol as a novel intervention for subclinical thyroid dysfunction

Summaries 3 min 17

Font Size

Created On: 07/05/2026

Myo-inositol is a naturally occurring compound recognized for its essential role in hormonal signal transduction, particularly as a precursor for phosphatidylinositol 4,5-bisphosphate.

See All

Key take away

Myo-inositol acts as a critical signal transducer that restores hormonal balance in individuals diagnosed with subclinical thyroid dysfunction.

Background

Myo-inositol is a naturally occurring compound recognized for its essential role in hormonal signal transduction, particularly as a precursor for phosphatidylinositol 4,5-bisphosphate. By activating phospholipase C cascades, it facilitates the cellular response to thyroid-stimulating hormone (TSH); consequently, its application has expanded from managing PCOS and metabolic disorders to addressing thyroid dysfunction. Researchers reviewed current scientific knowledge regarding the impact of myo-inositol supplementation on subclinical hypothyroidism.

Method

Literature search was executed across PubMed and Google Scholar to detect the relevant clinical data. The inclusion criteria specifically targeted studies focusing on the use of myo-inositol in patients with subclinical hypothyroidism. Conversely, investigations limited to overt hypothyroidism, euthyroid states, or unrelated pathologies were excluded from the review to ensure a focused analysis of subclinical thyroid modulation.

Result

The review of clinical evidence demonstrated that myo-inositol supplementation consistently reduced serum TSH levels in affected patients. Furthermore, participants showed a significant decline in anti-thyroid peroxidase (TPOAb) and anti-thyroglobulin (TgAb) antibodies, suggesting an immunomodulatory benefit. The intervention improved the overall health status of the patients and maintained an excellent safety profile, with only negligible side effects reported across the analyzed cohorts.

Conclusion

Myo-inositol is emerging as a safe, well-tolerated, and potentially effective therapeutic agent for subclinical hypothyroidism management. Current evidence supports its ability to improve thyroid function parameters and reduce autoimmune activity. Given its favorable safety profile and clinical benefits, myo-inositol holds strong potential to become a first-line adjunct therapy for subclinical hypothyroidism in the future, pending further large-scale trials.